SOCS2 and metabolic dysfunction-associated steatohepatitis: The expression of SOCS2 was significantly decreased in NAFLD, NASH and HCC, indicating that the persistent low expression of SOCS2 led to the malignant progression of benign liver lesions (Fig. 7G–K).